BTAI vs. CUE, ACRS, AFMD, SLS, VTVT, SPRO, ASMB, RLYB, JAGX, and HOOK
Should you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Cue Biopharma (CUE), Aclaris Therapeutics (ACRS), Affimed (AFMD), SELLAS Life Sciences Group (SLS), vTv Therapeutics (VTVT), Spero Therapeutics (SPRO), Assembly Biosciences (ASMB), Rallybio (RLYB), Jaguar Health (JAGX), and Hookipa Pharma (HOOK). These companies are all part of the "pharmaceutical preparations" industry.
Cue Biopharma (NASDAQ:CUE) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
BioXcel Therapeutics received 95 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 67.23% of users gave BioXcel Therapeutics an outperform vote while only 51.81% of users gave Cue Biopharma an outperform vote.
Cue Biopharma has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.
Cue Biopharma has a net margin of -711.84% compared to Cue Biopharma's net margin of -8,715.72%. BioXcel Therapeutics' return on equity of -128.30% beat Cue Biopharma's return on equity.
35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 10.2% of Cue Biopharma shares are held by company insiders. Comparatively, 35.8% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Cue Biopharma presently has a consensus target price of $8.00, suggesting a potential upside of 367.84%. BioXcel Therapeutics has a consensus target price of $16.71, suggesting a potential upside of 692.15%. Given Cue Biopharma's higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Cue Biopharma.
In the previous week, BioXcel Therapeutics had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 7 mentions for BioXcel Therapeutics and 5 mentions for Cue Biopharma. BioXcel Therapeutics' average media sentiment score of 1.38 beat Cue Biopharma's score of 0.34 indicating that Cue Biopharma is being referred to more favorably in the media.
Cue Biopharma has higher revenue and earnings than BioXcel Therapeutics. Cue Biopharma is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Cue Biopharma beats BioXcel Therapeutics on 11 of the 18 factors compared between the two stocks.
Get BioXcel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioXcel Therapeutics Competitors List
Related Companies and Tools
